Abstract
Cytotoxic T lymphocytes (CTLs) specific for the Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) antigen are important reagents for the treatment of some EBV-associated malignancies, such as EBV-positive Hodgkin's disease and nasopharyngeal carcinoma. However, the therapeutic amount of CTLs is often hampered by the limited supply of antigen-presenting cells. To address this issue, an artificial antigen-presenting cell (aAPC) was made by coating a human leukocyte antigen (HLA)-pLMP2 tetrameric complex, anti-CD28 antibody and CD54 molecule to a cell-sized latex bead, which provided the dual signals required for T cell activation. By co-culture of the HLA-A2-LMP2 bearing aAPC and peripheral blood mononuclear cells from HLA-A2 positive healthy donors, LMP2 antigen-specific CTLs were induced and expanded in vitro. The specificity of the aAPC-induced CTLs was demonstrated by both HLA-A2-LMP2 tetramer staining and cytotoxicity against HLA-A2-LMP2 bearing T2 cell, the cytotoxicity was inhibited by the anti-HLA class I antibody (W6/32). These results showed that LMP2 antigen-specific CTLs could be induced and expanded in vitro by the HLA-A2-LMP2-bearing aAPC. Thus, aAPCs coated with an HLA-pLMP2 complex, anti-CD28 and CD54 migh...Continue Reading
References
Jan 1, 1985·Immunogenetics·R D SalterP Cresswell
Jun 1, 1995·Immunological Reviews·C J Melief, W M Kast
Aug 1, 1994·Immunity·T L WalunasJ A Bluestone
Jan 1, 1995·Immunogenetics·H G RammenseeS Stevanoviíc
Jun 1, 1996·The Journal of Experimental Medicine·T L WalunasJ A Bluestone
Oct 4, 1996·Science·J D AltmanM M Davis
Feb 3, 1998·Journal of Immunological Methods·J CurtsingerM F Mescher
May 6, 1998·The Prostate·M L SalgallerG P Murphy
Aug 15, 1998·Vox Sanguinis·C M RooneyM K Brenner
Dec 16, 1998·Journal of Virology·I V Redchenko, A B Rickinson
Apr 1, 1999·Pharmaceutical Research·A J van RensenD J Crommelin
Aug 18, 1999·Proceedings of the National Academy of Sciences of the United States of America·W ReesJ Kappler
Apr 5, 2000·Nature Biotechnology·J B Latouche, M Sadelain
Dec 2, 2000·Nature Medicine·B PrakkenS Albani
Feb 28, 2001·Journal of Immunological Methods·E L ThamM F Mescher
Mar 10, 2001·European Journal of Immunology·Z SuM A Roskrow
Mar 9, 2002·Advances in Cancer Research·Stephen GottschalkCliona M Roon
Feb 14, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Marcela V MausCarl H June
Apr 22, 2003·Nature Medicine·Mathias OelkeJonathan P Schneck
Mar 20, 2004·Blood·Liesbeth E M OostenEls Goulmy
Mar 30, 2004·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Mathias Oelke, Jonathan P Schneck
Jun 3, 2004·The Journal of Experimental Medicine·Sophie PaczesnyA Karolina Palucka
Jul 6, 2004·Journal of Immunotherapy·Catherine M BollardCliona M Rooney
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edward A HirschowitzJohn Yannelli
Nov 16, 2004·Blood·Karin C M StraathofHelen E Heslop
Dec 22, 2004·The Journal of Experimental Medicine·Catherine M BollardHelen E Heslop